NOTCH3 and acute lymphoblastic leukemia: Our conclusions are supported by (I) reversion of HDACi effects on Notch3 levels by two different lysosome inhibitors and by blocking dynein function and (II) increased co-localization of Notch3 and the lysosomal marker LAMP2 in T-ALL cells treated with TSA by immunofluorescence studies and fractionation assays.